Treatment of severe forms of alcoholic hepatitis: Where are we going?
Article first published online: 12 MAR 2008
© 2007 The Authors
Journal of Gastroenterology and Hepatology
Special Issue: 2nd International Symposium on Alcoholic Liver and Pancreatic Diseases and Cirrhosis, Kobe, Japan
Volume 23, Issue Supplement s1, pages S60–S62, March 2008
How to Cite
Mathurin, P., Louvet, A. and Dharancy, S. (2008), Treatment of severe forms of alcoholic hepatitis: Where are we going?. Journal of Gastroenterology and Hepatology, 23: S60–S62. doi: 10.1111/j.1440-1746.2007.05286.x
- Issue published online: 12 MAR 2008
- Article first published online: 12 MAR 2008
- Accepted for publication 12 September 2007.
- alcoholic hepatitis;
- Lille model
Alcoholic hepatitis (AH) is observed in approximately 20% of heavy drinkers. The treatment of AH remains one of the main challenges to clinicians involved in the management of severe alcoholic liver disease. Corticosteroids improved the short-term survival of patients with severe AH. Nevertheless, the efficacy of corticosteroids is still considered controversial for some authors. Pentoxifylline may be considered an alternative to corticosteroids. Early identification of subjects with substantial risk of death according to the Lille model will improve management of patients suffering from severe AH and will aid in the design of future studies for alternative therapies. Alternative therapies are required to improve the prognosis of patients with a severe form of AH. Progress in understanding the pathogenesis of AH is opening up an exciting new era and is lending impetus to future evaluation of new drugs targeting the tumor necrosis factor pathways.